The Journal of family practice
-
Meta Analysis Comparative Study
Automated office BP measurement: The new standard in HTN screening.
Obtain greater accuracy in blood pressure measurement with an automated office device.
-
Meta Analysis Comparative Study
Is NPH associated with fewer adverse events than analog basal insulin for adults with T2D?
NO. Insulin glargine may lead to less patient-reported, symptomatic, and nocturnal hypoglycemia, although overall, there may not be a difference in the risk for severe hypoglycemia orhypoglycemiarelated emergency department (ED) visits and hospitalizations (strength of recommendation [SOR]: B, systematic review of randomized controlled trials [RCTs], individual RCTs, and observational study).
-
Diabetes is a progressive disease associated with micro- and macrovascular complications. Type 2 diabetes (T2D) is the leading contributor to chronic kidney disease (CKD) worldwide, which itself is associated with an increased burden of cardiovascular disease, increased risk of hypoglycemia, and increased risk of death beyond that caused by diabetes alone. In this video series available on The Journal of Family Practice website, the authors discuss how CKD in people with T2D is defined, potential consequences of CKD in this patient population, and how those with CKD and T2D should be identified, monitored, and treated. The authors discuss the best management approaches for CKD in those with T2D, including blood pressure control, renin-angiotensin-aldosterone system blockade, use of sodium-glucose cotransporter-2 inhibitors, and glycemic control. The importance of glycemic control in the prevention and reduction of CKD progression in people with T2D is reviewed, with an emphasis on the use of antihyperglycemic agents as renal function declines. Finally, the authors discuss the use of basal insulin in this patient population, emphasizing the importance of reaching glycemic control goals while minimizing hypoglycemia. They note that, in people with T2D and reduced renal function, second-generation basal insulin analogs have demonstrated comparable efficacy to first-generation basal insulin analogs in reducing HbA1c levels—but with less hypoglycemia.